Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q2 2022 Results Conference Call August 11, 2022 8:00 AM ET
Company Participants
Dr. Kimberly Lee - Chief Corporate Affairs Officer
RA Session - President, Founder, and Chief Executive Officer
Dr. Suyash Prasad - Chief Medical Officer and Head, R&D
Kamran Alam - Chief Financial Officer
Dr. Frederick Porter - Chief Technical Officer
Conference Call Participants
Joon Lee - Jo Securities
Gil Blum - Needham & Company
Mike Ulz - Morgan Stanley
Eun Yang - Jefferies
Jack Allen - Baird
Yun Zhong - BTIG
Sami Corwin - William Blair
Rick Miller - Cantor Fitzgerald
Operator
Greetings. Welcome to the Taysha Gene Therapies Second Quarter 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in listen-only mode. Following management's prepared remarks, we will hold a brief question-and-answer session. As a reminder, this call is being recorded today, August 11, 2022.
I'll now turn the call over to Dr. Kimberly Lee, Chief Corporate Affairs Officer. Please go ahead.
Dr. Kimberly Lee
Good morning, and welcome to Taysha's Second Quarter 2022 Financial Results and Corporate Update Conference Call. Joining me on today's call are RA Session, II Taysha's President, Founder and CEO; Dr. Frederick Porter, Chief Technical Officer; Dr. Suyash Prasad, Chief Medical Officer and Head of R&D; and Kamran Alam, Chief Financial Officer.
After our formal remarks, we will conduct a question-and-answer session and instructions will follow at that time. Earlier today, Taysha issued a press release announcing financial results for the second quarter ending June 30, 2022. A copy of this press release is available on the company's website and through our SEC filings.
Please note that on today's call, we will be making forward-looking statements, including statements relating to the safety and efficacy and the therapeutic and commercial potential of our investigational product candidates. These statements may include the expected timing and results of clinical trials for our product candidates, our expectations regarding the data necessary to support regulatory approval of TSHA-120 and the regulatory status and market opportunity for those programs as well as Taysha's manufacturing plans.
This call may also contain forward-looking statements relating to Taysha's growth and future operating results, discovery and development of product candidates, strategic alliances and intellectual property, as well as matters that are not of historical facts or information. Various risks may cause Taysha's actual results to differ materially from those stated or implied in such forward-looking statements.